Table 4.
Patients with hematologic and non-hematologic adverse events ≥ grade 3 following gemcitabine, carboplatin, dexamethasone, and rituximab (CTC 2.0)
| Hematologic category | Grade 3 | Grade 4 |
|---|---|---|
| Neutrophils | 17 | 21 |
| Hemoglobin | 17 | 1 |
| Hemorrhage | 5 | 0 |
| Infection | 12 | 0 |
| Platelets | 10 | 35 |
| Total patients with heme toxicity | 10 | 39 |
| Non-hematologic category | Grade 3 | Grade 4 |
| Allergy/Immunology | 2 | 0 |
| Cardiovascular | 6 | 1 |
| Constitutional | 4 | 1 |
| Gastrointestinal | 4 | 0 |
| Metabolic/Laboratory | 11 | 0 |
| Nausea | 2 | 0 |
| Neurology | 2 | 1 |
| Pain | 6 | 0 |
| Pulmonary | 3 | 0 |
| Total patients with non-heme toxicity | 23 | 2 |